PD-1 inhibitors block PD-1 receptors on host immune cells, whereas PD-L1 inhibitors block PD-L1 expressed on certain tumor cells, thus unleashing anti-tumor immune responses and producing anticancer effects (1, 2). Here, CD274 is linked to neoplasm.